Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia
Open Access
- 17 July 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 33 (5), 1100-1119
- https://doi.org/10.1093/schbul/sbm074
Abstract
Cognitive impairment is a core feature of schizophrenia as deficits are present in the majority of patients, frequently precede the onset of other positive symptoms, persist even with successful treatment of positive symptoms, and account for a significant portion of functional impairment in schizophrenia. While the atypical antipsychotics have produced incremental improvements in the cognitive func- tion of patients with schizophrenia, overall treatment remains inadequate. In recent years, there has been an in- creased interest in developing novel strategies for treating the cognitive deficits in schizophrenia, focusing on amelio- rating impairments in working memory, attention, and so- cial cognition. Here we review various molecular targets that are actively being explored for potential drug discov- ery efforts in schizophrenia and cognition. These molecular targetsinclude dopamine receptors inthe prefrontal cortex, nicotinic and muscarinic acetylcholine receptors, the gluta- matergic excitatory synapse, various serotonin receptors, and the g-aminobutyric acid (GABA) system.Keywords
This publication has 99 references indexed in Scilit:
- Cognitive improvement during Tolcapone treatment in Parkinson's diseaseJournal of Neural Transmission, 1997
- Catechol 0-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in ratsBehavioural Brain Research, 1997
- Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cellsNeuropsychopharmacology, 1996
- Genomic scan for genes predisposing to schizophreniaAmerican Journal of Medical Genetics, 1994
- Hypotensive and Bradycardic Effects Elicited by Spinal Dopamine Receptor StimulationJournal of Cardiovascular Pharmacology, 1991
- Clonidine improves memory function in schizophrenia independently from change in psychosis: Preliminary findingsSchizophrenia Research, 1988
- Structural brain pathology in schizophrenia revisited *1Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acidNeuropsychopharmacology, 1987
- Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in ratsPsychopharmacology, 1985
- Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenicsLife Sciences, 1983
- Cognitive Deficit Caused by Regional Depletion of Dopamine in Prefrontal Cortex of Rhesus MonkeyScience, 1979